NASDAQ
|
Healthcare
|
Drug Manufacturers—Specialty & Generic
Q322reported Nov 7, 2022 Reporting Period
$81.69M2.7%
vs. Q321
Revenues Q322
83.55%-2%
vs. Q321
Gross Profit Margin
-40.75%
!35.6%
vs. Q321 Net Profit Margin
-11.49M !51.5%
vs. Q321
Free Cash Flow Q322
$-0.12 !36.8%
vs. Q321
EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q223
Q223reported Nov 9, 2022 Reporting Period
$117.86M
-10.3%
vs. Q222
Revenues Q223
3.24%106%
vs. Q222 Gross Profit Margin
-188.19%
!-2135.8%
vs. Q222 Net Profit Margin
-135.75M !
-57.9% vs. Q222 Free Cash Flow Q223
$-0.47 !
-1466.7% vs. Q222 EPS Q223
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q223
Data not available for FOLD
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
2.47
2.31
Current Ratio
2.78
2.84
Cash Ratio
1.69
1.38
Price to Book
22.78
1
Price to Sales
36.96
13.76
Price to Earnings
-22.68
-1.83
Feedback
Disclaimer
The content of this website is for informational purposes only, you should not construe any such information or other material as legal, tax, investment,
financial, or other advice. Nothing contained on this website constitutes professional and/or financial advice, nor does any information on the website constitute a comprehensive or complete statement of the matters discussed or the law relating thereto.
In order to make the best financial decision that suits your own needs, you must conduct your own research and seek the advice of a licensed financial advisor if necessary.
Data
The financial data on StocksFin comes directly from SEC.gov.
We use a third party service (financialmodelingprep) to crawl, reprocess and organize such data in a readable manner. If you encounter any inacurracy in the data, please let us know.
We use Google Analytics to track users sessions on this website. You can block such tracking by using a GA opt-out add-on.
